Plus: Armor Health expands postpartum mental health program, Astrin Biosciences names new Medical Director, and SMFM clarifies abortion care's role.
The US Centers for Disease Control and Prevention (CDC) National Vital Statistics System reported a 73% increase in gestational hypertension incidence from 2016 to 2024, impacting maternal health solution providers. This data comes as organizations navigate evolving maternal and women's health needs, from postpartum mental health in correctional settings to the expansion of breast cancer detection technologies and the role of abortion care in high-risk pregnancies. Five takes inside, plus a quick-hits roundup.
Armor Health, a national provider of correctional healthcare, is expanding its structured approach to address postpartum depression (PPD) among women in correctional settings. This initiative focuses on maternal and hormonal health within a specific population.
Read the full story →Astrin Biosciences appointed Dr. Tanya Gupta as Medical Director, bringing medical oncology expertise. Concurrently, the cancer intelligence company expanded its Certitude™ Breast blood test nationwide. Certitude™ Breast offers early detection for breast cancer.
Read the full story →SMFM states abortion care is core to MFM practice. The organization urges institutional action to protect high-risk patient access. This position clarifies the role of abortion care within maternal-fetal medicine.
Read the full story →Etcamah, an oral SERD, recently fell short in first-line breast cancer. This marks the second oral SERD to demonstrate this outcome, following a similar setback from Roche.
Read the full story →Gestational hypertension incidence increased by 73% from 2016 to 2024, now affecting 1 in 10 pregnancies. The US Centers for Disease Control and Prevention (CDC) National Vital Statistics System reported these findings. This data highlights a growing patient need for maternal health solutions.
Read the full story →